Please join this Open Scientific Discussion (OSD) hosted by the AAPS Biopharmaceutical Product Attributes and Biological Consequences (BPABC) Community on Tuesday, July 23, 2024, 12 PM – 1 PM US EDT on:
A Mechanism-Based Dendritic Cell Migration Assay to Predict Subcutaneous Immunogenicity
Speaker / Discussion Leader: Nicole Jarvi, PhD (Merck)
Abstract: Subcutaneous (SC) delivery can exacerbate immunogenicity of biologics where injected protein is exposed to skin-derived dendritic cells (DC) migrating into the injection site and toward lymph nodes. In a newly developed, mechanism-based dendritic cell migration assay, chemokine receptor expression on DCs and their in vitro migration correlated strongly with clinical immunogenicity incidence. This assay can inform decision-making of SC immunogenicity risk, with applicability to screen formulation and quality attributes.
We look forward to your participation in a lively discussion on this topic!
When: July 23, 2024, 12 PM – 1 PM US EDT
Where: Please join Teams meeting using link provided below from your computer, tablet, or smartphone.
https://teams.microsoft.com/dl/launcher/launcher.html?url=%2F_%23%2Fl%2Fmeetup-join%2F19%3Ameeting_ZWY1MDlmNDctOWFmZS00YjIzLWFlMjAtZjY3YjUyN2U5NmM3%40thread.v2%2F0%3Fcontext%3D%257b%2522Tid%2522%253a%2522d7811cde-ecef-496c-8f91-a1786241b99c%2522%252c%2522Oid%2522%253a%2522da6f9c8c-317b-4a76-90c1-87ab430ab9a3%2522%257d%26anon%3Dtrue&type=meetup-join&deeplinkId=caf48aec-0da0-4b31-897d-1f41866dc25c&directDl=true&msLaunch=true&enableMobilePage=true&suppressPrompt=true
Please feel free to share meeting information with your colleagues who may be interested in this discussion.
Thank you,
BPABC Leadership Team
Related literature
- Jarvi, N. L., & Balu-Iyer, S. V. (2023). A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics. Communications Medicine, 3(1), 174.
- Jarvi, N. L., & Balu-Iyer, S. V. (2021). Immunogenicity challenges associated with subcutaneous delivery of therapeutic proteins. BioDrugs, 35(2), 125-146.
- Turner, M. R., & Balu-Iyer, S. V. (2018). Challenges and opportunities for the subcutaneous delivery of therapeutic proteins. Journal of pharmaceutical sciences, 107(5), 1247-1260.
- Hamuro, L., Kijanka, G., Kinderman, F., Kropshofer, H., Bu, D. X., Zepeda, M., & Jawa, V. (2017). Perspectives on subcutaneous route of administration as an immunogenicity risk factor for therapeutic proteins. Journal of Pharmaceutical Sciences, 106(10), 2946-2954.
------------------------------
Joshua Tokuda
Principal Scientist
Amgen
Newbury Park CA
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------